|
HUE036165T2
(hu)
|
2006-04-07 |
2018-06-28 |
Vertex Pharma |
ATP-kötõ kazetta transzportereinek modulátorai
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
MY188335A
(en)
|
2006-11-22 |
2021-11-30 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
CN102015716B
(zh)
|
2008-02-28 |
2014-09-17 |
诺华股份有限公司 |
用于治疗C-Met酪氨酸激酶介导的疾病的咪唑并[1,2-b]哒嗪衍生物
|
|
BRPI0912882A2
(pt)
*
|
2008-05-21 |
2017-05-16 |
Incyte Corp |
sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
JP2012511575A
(ja)
*
|
2008-12-12 |
2012-05-24 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
キナーゼ阻害剤としてのアザインドール誘導体
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
MX2011008452A
(es)
*
|
2009-02-10 |
2011-12-16 |
Astrazeneca Ab |
Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
|
|
WO2010104843A2
(en)
*
|
2009-03-09 |
2010-09-16 |
The Regents Of The University Of California |
Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EP2464649A1
(en)
|
2009-08-12 |
2012-06-20 |
Novartis AG |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
BR112012008061A2
(pt)
|
2009-08-20 |
2016-03-01 |
Novartis Ag |
compostos de oxima heterocíclica
|
|
RS63612B1
(sr)
*
|
2009-12-31 |
2022-10-31 |
Hutchison Medipharma Ltd |
Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションIncyte Corporation |
C−Met阻害剤としてのイミダゾ[1,2−b][1,2,4]トリアジン
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
SG10201505700QA
(en)
*
|
2010-04-22 |
2015-08-28 |
Vertex Pharma |
Process of producing cycloalkylcarboxamido-indole compounds
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
EA025281B9
(ru)
|
2010-05-17 |
2017-08-31 |
Инкозен Терапьютикс Пвт. Лтд. |
СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
|
|
US8513291B2
(en)
*
|
2010-06-01 |
2013-08-20 |
Angion Biomedica Corp. |
Cytochrome P450 inhibitors and uses thereof
|
|
US10414760B2
(en)
|
2016-11-29 |
2019-09-17 |
Angion Biomedica Corp. |
Cytochrome P450 inhibitors and uses thereof
|
|
AR085183A1
(es)
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
|
US20140088114A1
(en)
|
2011-05-16 |
2014-03-27 |
OSI Pharmaceuticals ,LLC |
Fused bicyclic kinase inhibitors
|
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
|
WO2013045519A1
(en)
|
2011-09-27 |
2013-04-04 |
Genfit |
Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
|
|
KR101869534B1
(ko)
*
|
2012-03-05 |
2018-06-20 |
한국화학연구원 |
신규한 트리아졸로 피리다진 유도체 및 그의 용도
|
|
NZ629499A
(en)
|
2012-03-30 |
2016-05-27 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
|
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
|
CN103122000B
(zh)
*
|
2012-09-03 |
2013-12-25 |
中美冠科生物技术(太仓)有限公司 |
用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
|
|
CN105209453B
(zh)
|
2012-10-16 |
2017-06-20 |
詹森药业有限公司 |
ROR‑γ‑T的亚甲基连接的喹啉基调节剂
|
|
MX2015004784A
(es)
|
2012-10-16 |
2015-08-14 |
Janssen Pharmaceutica Nv |
Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
|
|
JP6250686B2
(ja)
|
2012-10-16 |
2017-12-20 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Rorγtのヘテロアリール結合させたキノリニルモジュレータ
|
|
US9846345B2
(en)
|
2013-02-28 |
2017-12-19 |
Empire Technology Development Llc |
Colored pigment particles for electrophoretic displays
|
|
RU2018109979A
(ru)
*
|
2013-03-13 |
2019-02-28 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения бензоксазепиновых соединений
|
|
US20140303121A1
(en)
|
2013-03-15 |
2014-10-09 |
Plexxikon Inc. |
Heterocyclic compounds and uses thereof
|
|
PT2970265T
(pt)
*
|
2013-03-15 |
2018-10-23 |
Plexxikon Inc |
Compostos heterocíclicos e suas utilizações
|
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
|
BR112016008215A2
(pt)
|
2013-10-15 |
2017-09-26 |
Janssen Pharmaceutica Nv |
moduladores de quinolinila ligados por alquila de roryt
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
US9624225B2
(en)
|
2013-10-15 |
2017-04-18 |
Janssen Pharmaceutica Nv |
Quinolinyl modulators of RORγt
|
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
GB201321745D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2015134854A2
(en)
*
|
2014-03-06 |
2015-09-11 |
Oyagen, Inc. |
Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
|
|
CA2944140C
(en)
|
2014-04-15 |
2022-10-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
|
JP6578349B2
(ja)
|
2014-08-11 |
2019-09-18 |
アンジオン バイオメディカ コーポレーション |
チトクロームp450阻害剤およびその使用
|
|
JP2018501279A
(ja)
|
2014-12-31 |
2018-01-18 |
アンギオン バイオメディカ コーポレイション |
疾患を治療するための方法及び薬剤
|
|
RS61531B1
(sr)
*
|
2015-04-13 |
2021-04-29 |
Five Prime Therapeutics Inc |
Kombinovana terapija za kancer
|
|
IL305843B2
(en)
|
2015-07-20 |
2025-01-01 |
Genzyme Corp |
CSF-1R receptor antibodies
|
|
AU2018348241B2
(en)
|
2017-10-13 |
2023-01-12 |
Opna Bio SA |
Solid forms of a compound for modulating kinases
|
|
GB201905721D0
(en)
|
2019-04-24 |
2019-06-05 |
Univ Dundee |
Compounds
|
|
CN113861198B
(zh)
*
|
2020-06-30 |
2024-08-02 |
上海医药集团股份有限公司 |
咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
|
|
EP4267573A1
(en)
|
2020-12-23 |
2023-11-01 |
Genzyme Corporation |
Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
|